
FIGURE 1





Iris
Cornea
Pupil
Lens
Anterior Chamber
Posterior Chamber
Canal of Schlemm
Conjunctiva
Ciliary body
Suspensory ligament
Implant
Retina
Choroid
Sclera
Inferior rectus muscle
Fovea (in macula)
Retinal artery and vein
Optic nerve
Optic disc
Vitreous chamber

FIGURE 2



Zone clearance leaves voids and weakens gel
Gel begins to degrade and liquify
The hydrogel is fully degraded and resorbed
Drug gradually diffuses out of hydrogel ("zone clearance")

FIGURE 3




FIGURE 4A




FIGURE 4B




FIGURE 5A




FIGURE 5B



1 month
Normal retinal morphology
3 months
Normal retinal morphology
6 months
Normal retinal morphology

FIGURE 6




FIGURE 7A




FIGURE 7B



Implant
No Implant
Average Vascular Leakage Score
0
1
2
3
4
5
6
1
2
3
6
Time (Months)

FIGURE 8




FIGURE 9



0.5 months
1 month
3 months
6 months
9 months
12 months
24 months
38 months

FIGURE 10



Score Rating
0 = no leakage
4 = severe leakage
Untreated Controls
Group 1 2 Implants
Group 2 2Implants+ Avastin
errors bars are standard deviaton
Average Vascular Leakage Score
Time (Months)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
0
2
4
6
8
10
12
14
16
18
20
22

FIGURE 11



Control Eye - 1 month
Fluorescein leaking from vessels
No Inhibition
Leakage score = 4
Treated Eye - 1 month
Inhibition
Leakage score = 1

FIGURE 12



Untreated
Avastin®
Implant
Implast + Avastin®
Average Vascular Leakage Score
0
1
2
3
4
0
2
4
6
8
10
12
Time (Months)

FIGURE 13




FIGURE 14A




FIGURE 14B





FIGURE 15

FIGURE 16


Cohort 1 - Subject 1 (OS): Treatment Naïve Subject
BCVA
BASELINE
CSFT: 1252 µm
1.14 @ 1m (20/276)
MONTH 2
CSFT: 997 µm
1.10 @ 1m (20/252)
MONTH 4.5
CSFT: 975 µm
1.04 @ 1m (20/219)
MONTH 6
CSFT: 947 µm
1.10 @ 1m (20/252)
MONTH 9
CSFT: 901 µm
1.12 @ 1m (20/264)
MONTH 10.5
CSFT: 936 µm
1.10 @ 1m (20/252)



Mean Change from Baseline in CSFT (µm) ± SEM
250
150
50
-50
-150
-250
-350
-450
Pre-Treatment
Day 7
Day 14
Month 1
Month 2
Month 3
Month 4.5
Month 6
Month 7.5
Month 9
Month 11
Month 12
Month 14
Month 16
Cohort 1 (200 µg)
Cohort 2 (400 µg)
Cohort 3a (600 µg)
Cohort 3b (400 µg + Anti-VEGF)

FIGURE 17



Mean Change from Baseline in BCVA (ETDRS letters) ± SEM
30
25
20
15
10
5
0
-5
-10
-15
-20
-25
-30
Pre-Treatment
Day 7
Day 14
Month 1
Month 2
Month 3
Month 4.5
Month 6
Month 7.5
Month 9
Month 11
Month 12
Month 14
Month 16
Cohort 1 (200 µg)
Cohort 2 (400 µg)
Cohort 3a (600 µg)
Cohort 3b (400 µg + Anti-VEGF)

FIGURE 18

FIGURE 19

A



Cohort 2 - Subject 1 (OD):
Aflibercept for 16 months
BCVA
BASELINE
CSFT: 473 µm
-0.04
(20/18)
MONTH 2
CSFT: 368 µm
-0.06
(20/17)
MONTH 4.5
CSFT: 224 µm
0.30
(20/40)
MONTH 6
CSFT: 234 µm
-0.08
(20/17)
MONTH 7.5
CSFT: 295 µm
-0.08
(20/17)
MONTH 9
CSFT: 272 µm
-0.06
(20/17)
MONTH 10
CSFT: 251 µm
0.00
(20/20)
MONTH 11
CSFT: 275 µm
0.02
(20/21)
MONTH 12.5
CSFT: 375 µm
-0.12
(20/15)

FIGURE 19

B




FIGURE 20



Cohort 2 - Subject 7 (OD): Aflibercept for 6 years
BCVA
BASELINE
CSFT: 335 µm
0.54
(20/69)
MONTH 2
CSFT: 258 µm
0.30
(20/40)
MONTH 4.5
CSFT: 264 µm
0.30
(20/40)
MONTH 6
CSFT: 277 µm
0.32
(20/42)
MONTH 7.5
CSFT: 290 µm
0.5
(20/63)
MONTH 12
CSFT: 429 µm
0.5
(20/63)

FIGURE 21



Cohort 3a - Subject 1 (OS): Treatment Naïve Subject
BCVA
BASELINE
CSFT: 484 µm
0.58
(20/76)
DAY 7
CSFT: 457 µm
0.44
(20/55)
MONTH 2
CSFT: 236 µm
0.22
(20/33)
MONTH 3
CSFT: 232 µm
0.24
(20/40)
MONTH 4.5
CSFT: 267 µm
0.1
(20/25)
MONTH 6
CSFT: 289 µm
0.1
(20/25)
MONTH 7.5
CSFT: 242 µm
0.1
(20/25)

FIGURE 22




Cohort 3b - Subject 1 (OD): Treatment Naïve Subject
BCVA
BASELINE
CSFT: 423 µm
0.88
(20/152)
DAY 7
CSFT: 363 µm
0.76
(20/115)
MONTH 1
CSFT: 326 µm
0.64
(20/87)
MONTH 2
CSFT: 290 µm
0.62
(20/83)
MONTH 3
CSFT: 273 µm
0.66
(20/91)
MONTH 4.5
CSFT: 397 µm
0.66
(20/91)

FIGURE 23


Cohort 3b - Subject 2 (OS): Anti-VEGF for 7 Months
BCVA
BASELINE
CSFT: 599 µm
1.34
(20/438)
DAY 7
CSFT: 188 µm
1.1
(20/252)
MONTH 1
CSFT: 154 µm
1.1
(20/252)
MONTH 2
CSFT: 201 µm
1.1
(20/252)
MONTH 3
CSFT: 398.5 µm
1.1 @ 1M
(20/252)
Rescue therapy at Month 4.5




As Received
d50: 41µm
Agglomerates
Micronized
d50: 15µm
Volume Density (%)
0
5
10
15
0.1
1.0
10.0
100.0
1000.0
Size Classes (µm)

FIGURE 24

FIGURE 25

A


A

B





Ocular
TKI Injector
Polyimide Sleeve
ø0.41mm x
3.175mm
Nitinol Push Wire
ø0.23mm x 50mm
10µL Hamilton Syringe
Body
Plunger
(Gas-tite Hamilton 10µL
Syringe)
27G TW x 1 ¼"
Nipro Needle
Custom Housing
Custom Insert for Luer
Hub
PEG Tip
(not shown)

FIGURE 26


A


Plunger
Plunger Clip
Body Half
Cowl Half
25G x 13mm Needle
Cowl Plug


B




C


Plunger
Plunger Clip
2x Body Half
Kilfoil Wire


D


Cowl Cap
2x Cowl Half
25G Needle
25G Tipped
25G Needle (Shield)
OTX-TKI Implant 0.4mg

E



F






FIGURE 26G




FIGURE 26H

FIGURE 27




Screening
Monthly Follow-up
OIX-1K1
(actively enrolling subjects)
EVALUATION VISITS
2 weeks prior to Screening
Day 1
Day 3
Day 7
Day 14
Month 1
Month 2
Month 3
Month 4.5
Month 6
Month 7.5
Month 9
Month 14
DSMC
DSMC
Cohort 1: 200 µg (n=4)
Cohort 2: 400 µg (n=4)
Cohort 3a: 400 µg
Cohort 3b: 400 µg + anti-VEGF

FIGURE 28


Primary Efficacy Endpoint Month 7
0.6 mg OTX-TKI (N=90 subjects)
2 mg Aflibercept (N=90 subjects)
Screening/ Baseline/ Injection Day 1
Month 1
Month 2
Month 3
Month 4
Month 5
Month 6
Month 7
Month 8
Month 9
Month 10
Month 11
Month 12
EVALUATION VISITS
Single injection of 2 mg aflibercept
Sham aflibercept injection